You are here: Industry Insights > Celgene

News List

BMS acquires Celgene for an equity value of $74bn pharmaceutical-technology
January 04, 2019
Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement to acquire Celgene via a cash and stock transaction with an equity value of $74bn; Celgene shares have been valued at $102.43 per share.
BMS acquires Celgene for an equity value of $74bn pharmaceutical-technology
January 04, 2019
Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement to acquire Celgene via a cash and stock transaction with an equity value of $74bn; Celgene shares have been valued at $102.43 per share....
Bristol-Myers Squibb to buy Celgene for around $74 billion firstwordpharma
January 03, 2019
Bristol-Myers Squibb entered an agreement to acquire Celgene under a cash and stock transaction with an equity value of approximately $74 billion, the companies announced Thursday.
Celgene’s luspatercept aces phase 3 beta thalassemia trial fiercebiotech
January 03, 2019
A phase 3 trial of Celgene’s luspatercept in adults with beta thalassemia has hit its primary goal. The late-phase success tees Celgene to file for approval of its Acceleron-partnered blockbuster prospect in the first half of next year......
Celgene scores at ASH18 with double luspatercept data pharmaphorum
December 04, 2018
A pair of clinical trial wins for Celgene’s luspatercept at the American Society of Haematology (ASH) meeting have set up a filing for the new drug in mid-2019......
Dragonfly Therapeutics announces the expansion of its strategic collaboration with Celgene pharmaphorum
November 26, 2018
Dragonfly Therapeutics, Inc today announced that it has entered into an agreement with Celgene Corporation and its subsidiaries ("Celgene") to research...
Celgene notches positive Otezla data in scalp psoriasis as it guns for market expansion fiercepharma
October 11, 2018
When Celgene won FDA approval for its psoriasis pill Otezla in 2014, the company was entering a hugely competitive market that would become home to both established therapies and biotech newcomers from the likes ...
Celgene walks away from Oncomed’s navicixizumab pharmatimes
September 27, 2018
Celgene has decided not to exercise its option to license OncoMed's bispecific antibody navicixizumab.
Celgene walks away from Oncomed’s navicixizumab pharmatimes
September 21, 2018
Celgene has decided not to exercise its option to license OncoMed's bispecific antibody navicixizumab.
Agios, Celgene terminate partnership for developing cancer treatment biospectrum
September 10, 2018
Agios Pharmaceuticals and Celgene have mutually agreed to terminate their collaboration and license agreement inked on April 27, 2015, to develop and commercialize products containing pan-IDH inhibitor AG-881.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page